Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC boosted its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 11.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,622 shares of the biotechnology company's stock after buying an additional 14,668 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.22% of Blueprint Medicines worth $13,100,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hsbc Holdings PLC acquired a new stake in Blueprint Medicines during the second quarter valued at $1,060,000. Comerica Bank increased its position in shares of Blueprint Medicines by 2,582.9% during the 1st quarter. Comerica Bank now owns 10,839 shares of the biotechnology company's stock worth $1,028,000 after purchasing an additional 10,435 shares during the last quarter. Federated Hermes Inc. grew its stake in shares of Blueprint Medicines by 27.8% in the second quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company's stock valued at $6,721,000 after buying an additional 13,579 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Blueprint Medicines by 82.8% in the second quarter. SG Americas Securities LLC now owns 21,684 shares of the biotechnology company's stock worth $2,337,000 after acquiring an additional 9,819 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Blueprint Medicines by 3.2% during the first quarter. Vanguard Group Inc. now owns 6,309,977 shares of the biotechnology company's stock worth $598,564,000 after purchasing an additional 195,007 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Guggenheim lifted their price target on Blueprint Medicines from $130.00 to $138.00 and gave the stock a "buy" rating in a research report on Friday, August 2nd. Needham & Company LLC restated a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, November 15th. Wells Fargo & Company lowered their price objective on Blueprint Medicines from $153.00 to $151.00 and set an "overweight" rating for the company in a research report on Thursday, October 31st. Robert W. Baird increased their price target on shares of Blueprint Medicines from $112.00 to $127.00 and gave the stock an "outperform" rating in a research note on Friday, August 2nd. Finally, JMP Securities reissued a "market outperform" rating and set a $125.00 target price on shares of Blueprint Medicines in a research report on Monday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $122.11.

Insiders Place Their Bets

In other news, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total value of $324,499.56. Following the transaction, the insider now owns 69,070 shares of the company's stock, valued at $6,169,332.40. The trade was a 5.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.21% of the stock is owned by insiders.

Blueprint Medicines Stock Performance

Shares of NASDAQ:BPMC opened at $94.81 on Thursday. The business has a 50-day simple moving average of $90.00 and a two-hundred day simple moving average of $98.70. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. Blueprint Medicines Co. has a fifty-two week low of $64.79 and a fifty-two week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The company had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. During the same period in the previous year, the company posted ($2.20) EPS. The firm's revenue was up 126.5% on a year-over-year basis. Equities research analysts forecast that Blueprint Medicines Co. will post -3.66 EPS for the current fiscal year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.